Regeneron Pharmaceuticals, Inc. (REGN )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol REGN
- Company Regeneron Pharmaceuticals, Inc.
- Price $487.35
- Changes Percentage -0.6
- Change -2.93
- Day Low $481.58
- Day High $491.4
- Year High $1211.2
- Year Low $520.5
- Market Cap $64,260,937,720
- Price Avg 50 EMA (D) $594.46
- Price Avg 200 EMA (D) $794.95
- Exchange NASDAQ
- Volume 756,548
- Average Volume 1,150,490
- Open $491
- Previous Close $490.28
- EPS 39.36
- PE 15.38
- Earnings Announcement 2025-07-30 12:30:00
- Shares Outstanding $106,148,000
Company brief: REGENERON PHARMACEUTICALS, INC. (REGN )
- Healthcare
- Biotechnology
- Dr. Leonard S. Schleifer M.D., Ph.D.
- https://www.regeneron.com
- US
- N/A
- 04-02-1991
- US75886F1075
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
REGN Corporation News
REGN Stock Undervalued At $500?
forbes.com -- Regeneron Pharmaceuticals (NASDAQ:REGN) shares witnessed a notable 19% decline on Friday, May 30, in the wake of the unexpected failure of itepekimab, its chronic obstructive pulmonary disease (COPD) ...
Kymera Stock Jumps. New Dermatitis Pill Could Challenge Regeneron Blockbuster.
barrons.com -- Its dermatitis drug could win at least 10% of annual sales in dermatitis by 2030—or about $3 billion....
Regeneron's weight-loss drug helps preserve muscle mass in study
reuters.com -- Regeneron Pharmaceuticals said on Monday its experimental weight-loss drug combination helped preserve muscle mass in a mid-stage study....
S&P 500 Gains & Losses Today: Ulta Beauty Stock Soars; Regeneron Shares Plummet
investopedia.com -- Major U.S. equities indexes were mixed in the final session of the holiday-shortened trading week as President Donald Trump reverted to an antagonistic tone on trade with China and the latest Personal...
Regeneron dashes Wall Street's hopes as COPD treatment trial suffers a failure
marketwatch.com -- Regeneron's stock is having its worst day in 14 years after the failure of late-stage trial of its COPD treatment, after analysts had just placed a high probability of a positive result....
Regeneron shares plunge after mixed COPD drug trial results
proactiveinvestors.com -- Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) sank nearly 19% on Friday after the company's experimental COPD drug, developed with partner Sanofi SA (ADR) (NYSE:SNY), posted mixed results in t...
Regeneron shares slide on mixed trial data on smoker's lung drug
reuters.com -- Regeneron shares fell nearly 13% before the bell on Friday after its experimental drug for patients with a type of lung condition commonly called "smoker's lung" failed a late-stage trial, although it...
The Company Buying 23andMe Is a Pharmaceutical Giant. Here's How Investors Can Benefit From the Move.
fool.com -- Earlier this year, biotech company 23andMe filed for bankruptcy. The harsh reality was that its business, while enticing to people who wanted to learn about their backgrounds via DNA testing kits, was...